spironolactone has been researched along with Cardiotoxicity in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 7.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 3.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Lu, X | 1 |
| Wang, X | 1 |
| Qiu, Q | 1 |
| Zhu, P | 1 |
| Ma, L | 1 |
| Ma, X | 1 |
| Herrmann, J | 1 |
| Lin, X | 1 |
| Wang, W | 1 |
| Xu, X | 1 |
| Liu, G | 1 |
| Liu, Y | 1 |
| Wang, R | 1 |
| Hou, T | 1 |
| Chen, C | 1 |
| Zheng, S | 1 |
| Dong, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for spironolactone and Cardiotoxicity
| Article | Year |
|---|---|
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Cardiotoxicity; Doxorubicin; | 2021 |
Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
Topics: Action Potentials; Animals; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Collagen; Cytoprotection; | 2016 |